{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:27:17Z","timestamp":1791494837606,"version":"4.3.4"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["HIV\/STI\/18\/02\/2022-ECD-II"],"award-info":[{"award-number":["HIV\/STI\/18\/02\/2022-ECD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["37\/1743\/23\/EMR-II"],"award-info":[{"award-number":["37\/1743\/23\/EMR-II"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118190","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:24:07Z","timestamp":1758576247000},"page":"118190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["From antiretrovirals to curative therapies: Current developments in HIV treatment and prevention"],"prefix":"10.1016","volume":"300","author":[{"given":"Poonam","family":"Mundlia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Chaubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavitra","family":"Ranawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-5357","authenticated-orcid":false,"given":"Ravi Pratap","family":"Barnwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118190_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12916-015-0517-y","article-title":"HIV-1 functional cure: will the dream come true?","volume":"13","author":"Liu","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/molecules29020376","article-title":"Multitasking pharmacophores support Cabotegravir-based long-acting HIV pre-exposure prophylaxis (PrEP)","volume":"29","author":"Wan","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118190_bib3","unstructured":"https:\/\/www.unaids.org\/en\/resources\/fact-sheet, (n.d.)."},{"key":"10.1016\/j.ejmech.2025.118190_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118190_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The biology of the HIV-1 latent reservoir and implications for cure strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2025.118190_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/COH.0000000000000666","article-title":"Advances in cell and gene therapy for HIV disease: it is good to be specific","volume":"16","author":"David Pauza","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175173","article-title":"Treatment strategies for HIV infection with emphasis on role of CRISPR\/Cas9 gene: Success so far and road ahead","volume":"931","author":"Jena","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118190_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s13365-014-0308-9","article-title":"Genome editing strategies: potential tools for eradicating HIV-1\/AIDS","volume":"21","author":"Khalili","year":"2015","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.ejmech.2025.118190_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3389\/fimmu.2017.00995","article-title":"Modeling kick-kill strategies toward HIV cure","volume":"8","author":"Hernandez-Vargas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2016.00012","article-title":"Animal models for HIV cure research","volume":"7","author":"Policicchio","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001319","article-title":"Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal","volume":"4","author":"Bhatta","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.ejmech.2025.118190_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eimc.2018.01.007","article-title":"Strategies for the cure of HIV infection","volume":"37","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2019","journal-title":"Enferm. Infecc. Microbiol. Cl\u00edn."},{"key":"10.1016\/j.ejmech.2025.118190_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13174","article-title":"Successful optimization of antiretroviral regimens in treatment-experienced people living with HIV undergoing liver transplantation","volume":"21","author":"Waldman","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00126334-200406010-00007","article-title":"Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count","volume":"36","author":"Garc\u00eda","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2025.118190_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118190_bib16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/cid\/ciad366","volume":"77","author":"West","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1989983","article-title":"Effectiveness of antiretroviral treatment on the transition probability of immunological state of HIV\/AIDS patients: a markov chain model on the Iranian \u201cnational Registry of HIV\/AIDS Care\u201d database","volume":"2023","author":"Mirahmadizadeh","year":"2023","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2025.118190_bib18","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.2147\/IDR.S323762","article-title":"Intrapatient development of multi-class drug resistance in an individual infected with hiv-1 crf01_ae","volume":"14","author":"Peng","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejmech.2025.118190_bib19","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1021\/acs.molpharmaceut.5b00424","article-title":"Nanogel-conjugated reverse transcriptase inhibitors and their combinations as novel antiviral agents with increased efficacy against HIV-1 infection","volume":"12","author":"Senanayake","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118190_bib20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1345\/aph.1C388","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Grim","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118190_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir","volume":"47","author":"Yuen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118190_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/17415990802183876","article-title":"Lamivudine, an important drug in aids treatment","volume":"29","author":"Vasconcelos","year":"2008","journal-title":"J. Sulfur Chem."},{"key":"10.1016\/j.ejmech.2025.118190_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1098\/rsta.2009.0273","article-title":"Surface modification, functionalization and bioconjugation of colloidal Inorganic nanoparticles","volume":"368","author":"Sperling","year":"2010","journal-title":"Philos. Trans. R. Soc. A Math. Phys. Eng. Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","article-title":"Efavirenz","volume":"56","author":"Adkins","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118190_bib25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3389\/fphar.2018.01004","article-title":"Evaluation of oral antiretroviral drugs in mice with metabolic and neurologic complications","volume":"9","author":"Tsai","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118190_bib26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/tx8000972","article-title":"Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine","volume":"21","author":"Antunes","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118190_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/11208590-000000000-00000","article-title":"Rilpivirine","volume":"72","author":"Sanford","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118190_bib28","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/00003495-200363160-00003","article-title":"Atazanavir","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2025.118190_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2047-783X-14-S3-5","article-title":"Raltegravir: molecular basis of its mechanism of action","volume":"14","author":"Mouscadet","year":"2009","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118190_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-1293.2009.00759.x","article-title":"PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection","volume":"10","author":"Welch","year":"2009","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3851\/IMP1397","article-title":"Elvitegravir: a new HIV integrase inhibitor","volume":"20","author":"Shimura","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2025.118190_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077448","article-title":"Dolutegravir interactions with HIV-1 Integrase-DNA: structural rationale for drug resistance and dissociation kinetics","volume":"8","author":"DeAnda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118190_bib33","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2174\/092986706777935069","article-title":"A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20)","volume":"13","author":"Manfredi","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118190_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/hep.20074","article-title":"Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine","volume":"39","author":"Walker","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118190_bib35","first-page":"1543","article-title":"PURPOSE 2 study team, twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"390","author":"Kelley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/v16091368","article-title":"Treatment as the best prevention: twice-Yearly lenacapavir, a game changer in ending the AIDS epidemic","volume":"16","author":"Wen","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2025.118190_bib37","first-page":"5447","article-title":"Maraviroc: a review of its use in hivinfection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2025.118190_bib38","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1021\/acs.jmedchem.8b00759","article-title":"Discovery of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor Temsavir and its phosphonooxymethyl prodrug fostemsavir","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118190_bib39","author":"Ruzicka"},{"key":"10.1016\/j.ejmech.2025.118190_bib40","first-page":"18422","volume":"107","author":"Sevrioukova","year":"2010"},{"key":"10.1016\/j.ejmech.2025.118190_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/jrms.JRMS_689_18","article-title":"HIV drug resistance among na\u00efve HIV-infected patients in Iran","volume":"24","author":"Farrokhi","year":"2019","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib42","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"Sherman","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2025.118190_bib43","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.aids.0000327510.68503.e8","article-title":"HIV epidemiology and the effects of antiviral therapy on long-term consequences","volume":"22","author":"Quinn","year":"2008","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118190_bib44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/01.qai.0000179459.31562.16","article-title":"Comparisons of causes of death and mortality rates among HIV-infected persons","volume":"41","author":"Crum","year":"2006","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ejmech.2025.118190_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003510.pub2","article-title":"Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection","author":"Volmink","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118190_bib46","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1089\/apc.2016.0226","article-title":"Combining cell and gene therapy in an effort to eradicate HIV","volume":"30","author":"Wagner","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib47","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori","year":"2004","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.ejmech.2025.118190_bib48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118190_bib49","author":"Obeagu"},{"key":"10.1016\/j.ejmech.2025.118190_bib50","unstructured":"https:\/\/www.verywellhealth.com\/how-long-can-i-live-after-getting-hiv-48889, (n.d.). Accessed on 5th March 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib51","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: what we already know and questions that need to be answered","volume":"70","author":"Apostolova","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2025.118190_bib52","unstructured":"https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/hiv-and-hepatotoxicity, (n.d.). Accessed on 6th March 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/toxsci\/kfy159","article-title":"Nephrotoxicity and renal pathophysiology: a contemporary perspective","volume":"164","author":"Barnett","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib54","unstructured":"https:\/\/www.hiv.uw.edu\/page\/treatment\/drugs, (n.d.). Accessed on 6 March 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib55","unstructured":"https:\/\/go.drugbank.com\/drugs\/DB00649, (n.d.). Accessed on 8 March 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5415\/apallergy.2014.4.1.54","article-title":"Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management","volume":"4","author":"Yunihastuti","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.ejmech.2025.118190_bib57","series-title":"\u00c8ve Patients","first-page":"499","article-title":"Insights into the Reasons for Discontinuation of the \u00aeRst Highly Active Antiretroviral Therapy (HAART) Regimen in a Cohort of Antiretroviral Na\u00f5","volume":"14","author":"D\u2019","year":"2000"},{"key":"10.1016\/j.ejmech.2025.118190_bib58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","article-title":"Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions","volume":"130","author":"Lucas","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib59","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance, (n.d.). Accessed on 3 March 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib60","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0253-7613.96296","article-title":"Antiretroviral drugs: critical issues and recent advances","volume":"44","author":"Desai","year":"2012","journal-title":"Indian J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118190_bib61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/jamia.2001.0080527","article-title":"Clinical decision support systems for the practice of evidence-based medicine","volume":"8","author":"Sim","year":"2001","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"10.1016\/j.ejmech.2025.118190_bib62","series-title":"Machine Learning","author":"Mitchell","year":"1997"},{"key":"10.1016\/j.ejmech.2025.118190_bib63","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cmi.2019.09.009","article-title":"Machine learning for clinical decision support in infectious diseases: a narrative review of current applications","volume":"26","author":"Peiffer-Smadja","year":"2020","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.ejmech.2025.118190_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac487","article-title":"Predicting risk of multidrug-resistant Enterobacterales infections among people with HIV","volume":"9","author":"Henderson","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib66","article-title":"Machine learning to predict antimicrobial resistance: future applications in clinical practice?","volume":"54","author":"Kherabi","year":"2024","journal-title":"Infect. Dis. News"},{"key":"10.1016\/j.ejmech.2025.118190_bib67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0192623307309925","article-title":"Gene therapy: some history, applications, problems, and prospects","volume":"36","author":"Cotrim","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejmech.2025.118190_bib68","author":"Cavazzana-Calvo"},{"key":"10.1016\/j.ejmech.2025.118190_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1521-2254(200105\/06)3:3<201::AID-JGM195>3.0.CO;2-Z","article-title":"Gene therapy of severe combined immunodeficiencies","volume":"3","author":"Cavazzana-Calvo","year":"2001","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib70","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI30953","article-title":"Gene therapy for severe combined immunodeficiency: are we there yet?","volume":"117","author":"Cavazzana-Calvo","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118190_bib71","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3390\/ijms25052771","article-title":"Advances in HIV gene therapy","volume":"25","author":"Kitawi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib72","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0000000000000788","article-title":"Somatic cell-based therapy","volume":"99","author":"Hutchinson","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.ejmech.2025.118190_bib73","unstructured":"X. Ye, V.M. Rivera, P. Zoltick, F. Cerasoli, M.A. Schnell, G.-P. Cao, J. V Hughes, M. Gilman, J.M. Wilson, Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer, n.d. https:\/\/www.sciencemag.org. Accessed 10th May, 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fmed.2017.00182","article-title":"Regulatory and scientific advancements in gene therapy: state-of-the-art of clinical applications and of the supporting European regulatory framework","volume":"4","author":"Carvalho","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrg2985","article-title":"Ex vivo gene transfer and correction for cell-based therapies","volume":"12","author":"Naldini","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2025.118190_bib77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2010.06.014","article-title":"In vitro evolution and analysis of HIV-1 LTR-specific recombinases","volume":"53","author":"Buchholz","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2025.118190_bib78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.celrep.2016.03.042","article-title":"CRISPR\/Cas9-Derived mutations both inhibit HIV-1 replication and accelerate viral escape","volume":"15","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118190_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.67","article-title":"Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells","volume":"3","author":"DiGiusto","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejmech.2025.118190_bib80","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAI.0000000000001190","article-title":"TALEN-Mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus","volume":"74","author":"Shi","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2025.118190_bib81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12977-021-00581-1","article-title":"Editing out HIV: application of gene editing technology to achieve functional cure","volume":"18","author":"Xun","year":"2021","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejmech.2025.118190_bib82","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/14712598.2021.1865302","article-title":"HIV-1 cure strategies: why CRISPR?","volume":"21","author":"Atkins","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118190_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/481314","article-title":"HIV-1 genetic variability and clinical implications","author":"Santoro","year":"2013","journal-title":"ISRN Microbiol"},{"key":"10.1016\/j.ejmech.2025.118190_bib84","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib85","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118190_bib86","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","article-title":"HIV-1 remission and possible cure in a woman after haplo-cord blood transplant","volume":"186","author":"Hsu","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118190_bib87","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fcimb.2020.00424","article-title":"Block and lock HIV cure strategies to control the latent reservoir","volume":"10","author":"Ahlenstiel","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118190_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00495-19","article-title":"Alternate NF-\u03baB-Independent signaling reactivation of latent HIV-1 provirus","volume":"93","author":"Acchioni","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118190_bib89","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/v11121162","article-title":"Nuclear transit and HIV LTR binding of NF-\u03baB subunits held by I\u03baB proteins: implications for HIV-1 activation","volume":"11","author":"Khan","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2025.118190_bib90","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/JLB.5VMR0122-046RRR","article-title":"Shock and kill within the CNS: a promising HIV eradication approach?","volume":"112","author":"N\u00fchn","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2025.118190_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00699-21","article-title":"STING ligand-mediated priming of functional CD8+ T cells specific for HIV-1-Protective epitopes from naive T cells","volume":"95","author":"Kuse","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118190_bib92","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","article-title":"Deep latency: a new insight into a functional HIV cure","volume":"45","author":"Elsheikh","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2025.118190_bib93","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001754","article-title":"Systematic HIV-1 promoter targeting with CRISPR\/dCas9-VPR reveals optimal region for activation of the latent provirus","volume":"103","author":"Klinnert","year":"2022","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejmech.2025.118190_bib94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/aid.2014.0199","article-title":"Targeting NF-\u03baB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency","volume":"31","author":"Jiang","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.ejmech.2025.118190_bib95","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/v12121385","article-title":"Depicting hiv-1 transcriptional mechanisms: a summary of what we know","volume":"12","author":"Dutilleul","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2025.118190_bib96","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/v13061026","article-title":"Are bet inhibitors yet promising latency-reversing agents for hiv-1 reactivation in aids therapy?","volume":"13","author":"Salahong","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2025.118190_bib97","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fimmu.2018.00299","article-title":"Interferon-\u03b1 subtypes as an adjunct therapeutic approach for human immunodeficiency virus functional cure","volume":"9","author":"George","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780400","article-title":"SMAC mimetics as therapeutic agents in HIV infection","volume":"12","author":"Molyer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib99","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1097\/00002030-199912030-00012","article-title":"Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy","volume":"13","author":"Prins","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11904-012-0115-y","article-title":"Eliminating the HIV reservoir","volume":"9","author":"Lafeuillade","year":"2012","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.ejmech.2025.118190_bib101","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3389\/fmicb.2017.02007","article-title":"Curaxin CBL0100 blocks HIV-1 replication and reactivation through inhibition of viral transcriptional elongation","volume":"8","author":"Jean","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118190_bib102","unstructured":"https:\/\/www.excision.bio\/news\/press-releases\/detail\/43\/excision-biotherapeutics-announces-data-from-the-phase-12, (n.d.). Accessed on 15 May, 2024."},{"key":"10.1016\/j.ejmech.2025.118190_bib103","article-title":"Multiple treatment interruptions and protecting HIV-specific CD4 T-Cells enables durable CTL response and viral control","author":"Jain","year":"2023","journal-title":"Preprint"},{"key":"10.1016\/j.ejmech.2025.118190_bib104","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ejmech.2025.118190_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.792684","article-title":"The CCR5 gene edited CD34+CD90+ hematopoietic stem cell population serves as an optimal graft source for HIV gene therapy","volume":"13","author":"Karuppusamy","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib106","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/hum.2020.159","article-title":"HIV gene therapy: an update","volume":"32","author":"Cornu","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejmech.2025.118190_bib107","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/COH.0000000000000857","article-title":"Pediatric immunotherapy and HIV control","volume":"19","author":"Chinunga","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib108","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1517\/14712598.2014.950652","article-title":"Advances in dendritic cell immunotherapies for HIV-1 infection","volume":"14","author":"Miller","year":"2014","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118190_bib109","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1371\/journal.ppat.1000055","article-title":"Control of viremia and prevention of AIDS following immunotherapy of SIV-Infected macaques with peptide-pulsed blood","volume":"4","author":"De Rose","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2025.118190_bib110","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3389\/fimmu.2019.02060","article-title":"Immunotherapy in people with HIV and cancer","volume":"10","author":"Puronen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib111","first-page":"263","article-title":"The rational combination strategy of immunomodulatory latency reversing agents and novel immunotherapy to achieve HIV-1 cure","volume":"2","author":"Li","year":"2022","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.ejmech.2025.118190_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21239151","article-title":"Photoimmunotherapy using cationic and anionic photosensitizer-antibody conjugates against hiv env-expressing cells","volume":"21","author":"Sadraeian","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib113","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118190_bib114","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2796.2010.02221.x","article-title":"Impact of \u03b3-chain cytokines on T cell homeostasis in HIV-1 infection: therapeutic implications: symposium","volume":"267","author":"Gougeon","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1742-4690-9-72","article-title":"Can immunotherapy be useful as a \u201cfunctional cure\u201d for infection with human immunodeficiency Virus-1?","volume":"9","author":"Vanham","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejmech.2025.118190_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25829","article-title":"Broadly neutralizing monoclonal antibodies for HIV prevention","volume":"24","author":"Miner","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib117","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/19420862.2017.1311435","article-title":"Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults","volume":"9","author":"Huang","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2025.118190_bib118","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib119","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/pbi.12137","article-title":"Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco","volume":"12","author":"Teh","year":"2014","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.ejmech.2025.118190_bib120","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Li","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118190_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1006952","article-title":"Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features","volume":"15","author":"Magaret","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejmech.2025.118190_bib122","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.virol.2012.06.025","article-title":"Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model","volume":"432","author":"Veselinovic","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2025.118190_bib123","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01762-16","article-title":"Broadly neutralizing antibodies display potential for prevention of HIV-1 infection of mucosal tissue superior to that of nonneutralizing antibodies","volume":"91","author":"Cheeseman","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118190_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28727-5","article-title":"First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody","volume":"13","author":"Beckford-Vera","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118190_bib125","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-Uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib127","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review","volume":"223","author":"Mahomed","year":"2021","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.ejmech.2025.118190_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118190_bib130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/ID9.0000000000000025","article-title":"Moving toward a functional cure for HIV-1","volume":"1","author":"Kang","year":"2021","journal-title":"Infectious Diseases and Immunity"},{"key":"10.1016\/j.ejmech.2025.118190_bib131","article-title":"CD160 promotes NK cell functions by upregulating glucose metabolism and negatively correlates with HIV disease progression","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib132","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.18.1.20497","article-title":"Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions","volume":"18","author":"Graziani","year":"2015","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib133","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/icb.2010.118","article-title":"Human immunodeficiency virus-1 vaccine design: where do we go now","volume":"89","author":"Wijesundara","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118190_bib134","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1002\/eji.201545513","article-title":"Toward a cure for HIV-seeking effective therapeutic vaccine strategies","volume":"45","author":"Autran","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118190_bib135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12069","article-title":"CD8+ T-cell effector function and transcriptional regulation during HIV pathogenesis","volume":"254","author":"Demers","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2025.118190_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/954806","article-title":"Innate immune evasion strategies by human immunodeficiency virus type 1","volume":"2013","author":"Guha","year":"2013","journal-title":"ISRN AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib137","first-page":"1","article-title":"HIV mRNA vaccines\u2014progress and future paths","volume":"9","author":"Mu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2025.118190_bib138","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1172\/JCI99005","article-title":"TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs","volume":"128","author":"Cheng","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118190_bib139","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jmv.20612","article-title":"Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial","volume":"78","author":"Ide","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2025.118190_bib140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection","volume":"66","author":"Kim","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib141","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/CS20050157","article-title":"Therapeutic vaccination against HIV: current progress and future possibilities","volume":"110","author":"Puls","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ejmech.2025.118190_bib142","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo","volume":"214","author":"Medina-Ram\u00edrez","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"Soluble HIV-1 env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2025.118190_bib144","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(13)70343-8","article-title":"Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial","volume":"14","author":"Pollard","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib145","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1038\/s41598-020-61878-3","article-title":"Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 infection","volume":"10","author":"Gay","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118190_bib146","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/v12040415","article-title":"TAT-based therapies as an adjuvant for an HIV-1 functional cure","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2025.118190_bib147","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines2010160","article-title":"DNA\/MVA vaccines for HIV\/AIDS","volume":"2","author":"Iyer","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2025.118190_bib148","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","article-title":"Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption","volume":"26","author":"Colby","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib149","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2025.118190_bib150","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/14760584.2.6.739","article-title":"The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection","volume":"2","author":"Fern\u00e1ndez-Cruz","year":"2003","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejmech.2025.118190_bib151","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib152","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4161\/hv.6.2.11331","article-title":"The RV144 Thai HIV vaccine trial","volume":"6","author":"Plotkin","year":"2010","journal-title":"Hum. Vaccines"},{"key":"10.1016\/j.ejmech.2025.118190_bib153","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ejmech.2025.118190_bib154","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/bit.26498","article-title":"cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate","volume":"115","author":"Dey","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejmech.2025.118190_bib155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/vaccines7040209","article-title":"Therapeutic vaccine in chronically Hiv-1-infected patients: a randomized, double-blind, placebocontrolled phase IIa trial with HTI-Trimix","volume":"7","author":"de Jong","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2025.118190_bib156","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1570162052772924","article-title":"HIV-1 TAR RNA: the target of molecular interactions between the virus and its host","volume":"3","author":"Bannwarth","year":"2005","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.ejmech.2025.118190_bib157","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/jmbi.1999.3060","article-title":"Tackling tat","volume":"293","author":"Karn","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118190_bib158","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","article-title":"Controlling the elongation phase of transcription with P-TEFb","volume":"23","author":"Peterlin","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118190_bib159","doi-asserted-by":"crossref","first-page":"12973","DOI":"10.1073\/pnas.1806438115","article-title":"Structural mechanism for HIV-1 TAR loop recognition by tat and the super elongation complex","volume":"115","author":"Schulze-Gahmen","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118190_bib160","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2010.04.013","article-title":"HIV-1 tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription","volume":"38","author":"He","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118190_bib161","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.molcel.2010.04.012","article-title":"HIV-1 tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP","volume":"38","author":"Sobhian","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118190_bib162","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4161\/cc.28756","article-title":"Crystal structure of HIV-1 tat complexed with human P-TEFb and AFF4","volume":"13","author":"Gu","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2025.118190_bib163","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nature09131","article-title":"Crystal structure of HIV-1 tat complexed with human P-TEFb","volume":"465","author":"Tahirov","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118190_bib164","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1006\/jmbi.1999.2933","article-title":"Direct evidence that HIV-1 tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation","volume":"290","author":"Isel","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118190_bib165","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmcl.2014.11.004","article-title":"Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR","volume":"24","author":"Zeiger","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118190_bib166","doi-asserted-by":"crossref","first-page":"15684","DOI":"10.1073\/pnas.0900629106","article-title":"Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of tat protein","volume":"106","author":"Davidson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118190_bib167","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.1021\/acs.jmedchem.6b01450","article-title":"Development of small molecules with a noncanonical binding mode to HIV-1 trans activation response (TAR) RNA","volume":"59","author":"Abulwerdi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118190_bib168a","series-title":"RNA Recognition by Tat-Derived Peptides: Interaction in the Major Groove?","author":"Weeks","year":"1991"},{"key":"10.1016\/j.ejmech.2025.118190_bib168b","first-page":"1281","volume":"249","author":"Weeks","year":"1990","journal-title":"Fragments of the HIV-1 Tat protein specifically bind TAR RNA, Science"},{"key":"10.1016\/j.ejmech.2025.118190_bib169","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/nar\/gky1197","article-title":"An ultra-high affinity ligand of HIV-1 TAR reveals the RNA structure recognized by P-TEFb","volume":"47","author":"Shortridge","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118190_bib170","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1002\/j.1460-2075.1990.tb07637.x","article-title":"HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure","volume":"9","author":"Dingwall","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118190_bib171","doi-asserted-by":"crossref","first-page":"6925","DOI":"10.1073\/pnas.86.18.6925","article-title":"Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro","volume":"86","author":"Dingwall","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118190_bib172","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.2205002","article-title":"Fragments of the HIV-1 tat protein specifically bind TAR RNA","volume":"249","author":"Weeks","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118190_bib173","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.4.8.1365","article-title":"A bulge structure in HIV-1 TAR RNA is required for tat binding and Tat-mediated trans-activation","volume":"4","author":"Roy","year":"1990","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.118190_bib174","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/jmbi.1993.1128","article-title":"High affinity binding of TAR RNA by the human immunodeficiency virus Type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region","volume":"230","author":"Churcher","year":"1993","journal-title":"J. Mol. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118190_bib175","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1073\/pnas.89.7.2723","article-title":"Specific binding of arginine to TAR RNA","volume":"89","author":"Tao","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118190_bib176","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jmb.2003.12.028","article-title":"Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA","volume":"336","author":"Murchie","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118190_bib177","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/nar\/26.8.1991","article-title":"NMR evidence for a base triple in the HIV-2 TAR C-G\u00b7C+ mutant-argininamide complex","volume":"26","author":"Brodsky","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118190_bib178","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jmb.2003.12.046","article-title":"Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic \u201cHot Spots,\u201d","volume":"336","author":"Davis","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"40","key":"10.1016\/j.ejmech.2025.118190_bib179","doi-asserted-by":"crossref","first-page":"14204","DOI":"10.1021\/bi981308u","article-title":"Inhibitors of Protein\u2212RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules","volume":"37","author":"Mei","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118190_bib180","doi-asserted-by":"crossref","unstructured":"Mei, H.; Mack, D. P.; Galan, A.; Halim, N. S.; Heldsinger, A.; Loo, J. A.; Moreland, D. W.; Sannes\u2010Lowery, K. A.; Lamia Sharmeen; Truong, H. N.; Czarnik, A. W. Discovery of selective, small-molecule inhibitors of RNA Complexes\u20141. The tat Protein\/TAR RNA complexes required for HIV-1 transcription. Bioorg. Med. Chem., 5 (6), 1173\u20131184. https:\/\/doi.org\/10.1016\/s0968-0896(97)00064-3.","DOI":"10.1016\/S0968-0896(97)00064-3"},{"key":"10.1016\/j.ejmech.2025.118190_bib181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002038","article-title":"Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the tat-transactivating response element (TAR) RNA","volume":"7","author":"Lalonde","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2025.118190_bib182","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1021\/bi0619371","article-title":"Structure-guided peptidomimetic design leads to nanomolar \u03b2-hairpin inhibitors of the Tat-TAR interaction of bovine immunodeficiency virus","volume":"46","author":"Athanassiou","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118190_bib183","doi-asserted-by":"crossref","first-page":"12362","DOI":"10.1021\/bi0510532","article-title":"TAR RNA recognition by a cyclic peptidomimetic of tat protein","volume":"44","author":"Leeper","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118190_bib184","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/nar\/gkq713","article-title":"Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of tat protein","volume":"39","author":"Davidson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118190_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2023.1101483","article-title":"Assessment of anti-HIV-1 guide RNA efficacy in cells containing the viral target sequence, corresponding gRNA, and CRISPR\/Cas9","author":"Allen","year":"2023","journal-title":"Front Genome"},{"key":"10.1016\/j.ejmech.2025.118190_bib186","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/cid\/ciq243","article-title":"The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection","volume":"52","author":"Gardner","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib187","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11904-014-0228-6","article-title":"Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches","volume":"11","author":"Brown","year":"2014","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.ejmech.2025.118190_bib188","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0b013e3283536ab2","article-title":"Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer","volume":"7","author":"El-Bassel","year":"2012","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib189","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26229","article-title":"Understanding effective post-test linkage strategies for HIV prevention and care: a scoping review","volume":"27","author":"Wamuti","year":"2024","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib190","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1037\/0033-2909.131.6.856","article-title":"A test of major assumptions about behavior change: a comprehensive look at the effects of passive and active HIV-prevention interventions since the beginning of the epidemic","volume":"131","author":"Albarrac\u00edn","year":"2005","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.ejmech.2025.118190_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276801","article-title":"The role of religious leaders on the use of HIV\/AIDS prevention strategies among young people (15\u201324) in Lira district, Uganda","volume":"17","author":"Murungi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118190_bib192","doi-asserted-by":"crossref","first-page":"17","DOI":"10.59298\/IDOSR\/JES\/101.1.7002","article-title":"Occurrence and factors associated with HIV-Sero-Discordance in couples at Iganga general hospital-iganga district, Eastern Uganda","author":"Yasin","year":"2023","journal-title":"IDOSR JOURNAL OF EXPERIMENTAL SCIENCES"},{"key":"10.1016\/j.ejmech.2025.118190_bib193","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11904-010-0063-3","article-title":"Combination HIV prevention: significance, challenges, and opportunities","volume":"8","author":"Kurth","year":"2011","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.ejmech.2025.118190_bib194","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1258\/ijsa.2011.011173","article-title":"Persons at high risk for HIV infection in Kisumu, Kenya: identifying recruitment strategies for enrolment in HIV-prevention studies","volume":"23","author":"Ogendo","year":"2012","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/sextrans-2013-051250","article-title":"Distinguishing sources of HIV transmission from the distribution of newly acquired HIV infections: why is it important for HIV prevention planning?","volume":"90","author":"Mishra","year":"2014","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.ejmech.2025.118190_bib196","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1080\/13691058.2020.1720821","article-title":"Ethics and the treatment as prevention strategy among transgender women living with HIV in Argentina","volume":"23","author":"Zalazar","year":"2021","journal-title":"Cult. Health Sex."},{"key":"10.1016\/j.ejmech.2025.118190_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25452","article-title":"Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART)","volume":"23","author":"Eshleman","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib198","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1016\/S2352-3018(19)30226-7","article-title":"The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment","volume":"6","author":"Baral","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ejmech.2025.118190_bib199","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.mpmed.2022.01.007","article-title":"HIV prevention strategies","volume":"50","author":"Cabecinha","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.ejmech.2025.118190_bib200","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib201","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dewb.12026","article-title":"Ethics of ARV based prevention: Treatment-as-prevention and PrEP","volume":"13","author":"Haire","year":"2013","journal-title":"Develop. World Bioeth."},{"key":"10.1016\/j.ejmech.2025.118190_bib202","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/COH.0b013e32835369ad","article-title":"Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention","volume":"7","author":"Strathdee","year":"2012","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib203","article-title":"Research priorities to end the adolescent HIV epidemic in the United States: viewpoint","volume":"10","author":"Isabel Fernandez","year":"2021","journal-title":"JMIR Res. Protoc."},{"key":"10.1016\/j.ejmech.2025.118190_bib204","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118190_bib205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12879-023-08873-x","article-title":"Analysis of HIV drug prophylaxis services cascade in healthcare workers: a cross-sectional study in China","volume":"24","author":"Hu","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib206","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib207","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25419","article-title":"Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review","volume":"22","author":"Elliott","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib208","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25298","article-title":"HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery","volume":"22","author":"Celum","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib209","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.2.21295","article-title":"Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach","volume":"20","author":"Seidman","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib210","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf116","article-title":"Lenacapavir for human immunodeficiency virus (HIV) prevention: a commitment to equitable access and partnership by gilead sciences","author":"Baeten","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib211","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/21505594.2025.2497902","article-title":"Lenacapavir's success: revitalizing antiviral drug discovery","volume":"16","author":"Miranda","year":"2025","journal-title":"Virulence"},{"key":"10.1016\/j.ejmech.2025.118190_bib212","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11904-016-0312-1","article-title":"PrEP as peri-conception HIV prevention for women and men","volume":"13","author":"Heffron","year":"2016","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.ejmech.2025.118190_bib213","doi-asserted-by":"crossref","first-page":"917","DOI":"10.46234\/ccdcw2020.250","article-title":"A pilot program of pre-exposure and post-exposure prophylaxis promotion among men who have sex with men \u2014 7 study sites, China, 2018\u20132019","volume":"2","author":"Wang","year":"2020","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.ejmech.2025.118190_bib214","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/apc.2021.0197","article-title":"Why do HIV pre-exposure prophylaxis users discontinue pre-exposure prophylaxis care? A mixed methods survey in a pre-exposure prophylaxis clinic in Belgium","volume":"36","author":"Vanbaelen","year":"2022","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.ejmech.2025.118190_bib215","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy099","article-title":"Provider adherence to pre-exposure prophylaxis monitoring guidelines in a large primary care network","volume":"5","author":"Spinelli","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118190_bib216","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40273-013-0111-0","article-title":"Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US","volume":"31","author":"Hellinger","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejmech.2025.118190_bib217","first-page":"319","article-title":"A mathematical model for HIV\/AIDS under pre-exposure and post-exposure prophylaxis","volume":"11","author":"Moya","year":"2022","journal-title":"Bio-Math."},{"key":"10.1016\/j.ejmech.2025.118190_bib218","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12889-020-10135-3","article-title":"Knowledge of PEP and PrEP among people living with HIV\/AIDS in Brazil","volume":"21","author":"Sousa","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejmech.2025.118190_bib219","first-page":"2","article-title":"Facing medical care problems of victims of sexual violence in goma\/Eastern democratic Republic of the Congo, confl","volume":"5","author":"Baelani","year":"2011","journal-title":"Health"},{"key":"10.1016\/j.ejmech.2025.118190_bib220","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.17.1.19228","article-title":"The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review","volume":"17","author":"Remme","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib221","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25670","article-title":"Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda","volume":"24","author":"Ayieko","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejmech.2025.118190_bib222","doi-asserted-by":"crossref","first-page":"32","DOI":"10.11604\/pamj.2015.21.32.4996","article-title":"Post exposure prophylaxis following occupational exposure to HIV: a survey of health care workers in Mbeya, Tanzania, 2009-2010","volume":"21","author":"Mponela","year":"2015","journal-title":"Pan African Medical Journal"},{"key":"10.1016\/j.ejmech.2025.118190_bib223","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/hiv.12075","article-title":"Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence","volume":"15","author":"Mcallister","year":"2014","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2025.118190_bib224","first-page":"179","article-title":"Knowledge and practice of post-exposure prophylaxis (PEP) against HIV infection among health care providers in a tertiary hospital in Nigeria","volume":"11","author":"Owolabi","year":"2012","journal-title":"J. Int. Assoc. Phys. AIDS Care"},{"key":"10.1016\/j.ejmech.2025.118190_bib225","article-title":"Prevalence of occupational exposure to HIV and factors associated with compliance with post-exposure prophylaxis among health workers of the Biyem-Assi, buea, and limbe health districts of Cameroon maternal and child health and AIDS","volume":"11","author":"Esum","year":"2022","journal-title":"International Journal of Maternal and Child Health and AIDS (IJMA)"},{"key":"10.1016\/j.ejmech.2025.118190_bib226","first-page":"108","article-title":"Assessment of the knowledge, attitude and practice of health care workers in Fako division on post exposure prophylaxis to blood borne viruses: a hospital based cross-sectional study, Pan Afr","volume":"31","author":"Ngwa","year":"2018","journal-title":"Med. J."},{"key":"10.1016\/j.ejmech.2025.118190_bib227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00203-024-03846-3","article-title":"Fighting nature with nature: antiviral compounds that target retroviruses","volume":"206","author":"Siew","year":"2024","journal-title":"Arch. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118190_bib228","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118190_bib229","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","article-title":"Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds","volume":"20","author":"Pauwels","year":"1988","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejmech.2025.118190_bib230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/07391102.2017.1420489","article-title":"Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV","volume":"37","author":"Vora","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2025.118190_bib231","doi-asserted-by":"crossref","first-page":"174","DOI":"10.31083\/j.fbl2705152","article-title":"Simple theoretical criterion for selection of natural compounds with anti-COVID-19 activity","volume":"27","author":"Veljkovic","year":"2022","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2025.118190_bib232","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.biochi.2025.07.017","article-title":"Small molecule based targeting of the CssA RNA thermometer: insights from computational and biophysical studies","volume":"237","author":"Sharma","year":"2025","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2025.118190_bib233","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/17568919.2025.2520152","article-title":"RNA targeting therapeutics: drugging the undruggable","volume":"17","author":"Mundlia","year":"2025","journal-title":"Future Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:46:07Z","timestamp":1773125167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":234,"alternative-id":["S0223523425009559"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118190","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From antiretrovirals to curative therapies: Current developments in HIV treatment and prevention","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118190"}}